ArticleCells2024

The CDK Inhibitor Dinaciclib Improves Cisplatin Response in Nonseminomatous Testicular Cancer: A Preclinical Study.

Elisa Rossini et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.